Omada Health (NASDAQ:OMDA) President Sells 8,866 Shares

Omada Health, Inc. (NASDAQ:OMDAGet Free Report) President Wei-Li Shao sold 8,866 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $25.02, for a total transaction of $221,827.32. Following the sale, the president directly owned 307,372 shares in the company, valued at $7,690,447.44. The trade was a 2.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Wei-Li Shao also recently made the following trade(s):

  • On Friday, June 12th, Wei-Li Shao sold 4,589 shares of Omada Health stock. The shares were sold at an average price of $17.24, for a total transaction of $79,114.36.

Omada Health Stock Performance

Shares of OMDA traded down $0.17 during trading hours on Wednesday, hitting $23.84. The stock had a trading volume of 1,552,408 shares, compared to its average volume of 1,274,695. The firm has a 50-day moving average price of $20.61 and a 200 day moving average price of $16.32. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of 476.80 and a beta of 1.73.

Omada Health (NASDAQ:OMDAGet Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.10. Omada Health had a net margin of 1.39% and a return on equity of 2.67%. The company had revenue of $87.83 million for the quarter, compared to analyst estimates of $80.93 million. As a group, analysts predict that Omada Health, Inc. will post -0.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Omada Health

Large investors have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new position in shares of Omada Health in the second quarter worth about $32,000. Bellevue Group AG lifted its position in Omada Health by 0.7% during the third quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock worth $5,567,000 after buying an additional 1,791 shares in the last quarter. Quarry LP acquired a new position in Omada Health during the fourth quarter worth $29,000. Barclays PLC grew its holdings in Omada Health by 14.6% in the 4th quarter. Barclays PLC now owns 14,850 shares of the company’s stock valued at $234,000 after buying an additional 1,888 shares in the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new stake in Omada Health in the 4th quarter valued at $32,000.

Omada Health News Roundup

Here are the key news stories impacting Omada Health this week:

  • Positive Sentiment: Omada’s second-quarter results provided further evidence that revenue growth is translating into profitability. The company reported earnings of $0.08 per share versus a consensus loss of $0.02 and revenue of approximately $87.8 million, well above the $80.9 million analyst estimate. The results support the bullish case for Omada’s digital chronic-care platform and improving financial execution. Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
  • Positive Sentiment: Robert W. Baird raised its price target on OMDA from $15 to $25, reflecting improved expectations following the earnings performance. However, the firm maintained a neutral rating, indicating that much of the near-term upside may already be reflected in the stock price. Benzinga analyst update
  • Neutral Sentiment: Analyst sentiment remains broadly favorable, with a reported consensus rating of “Moderate Buy” and an average price target of $25.67. Recent targets range from $24 to $35, but the wide range highlights uncertainty around valuation and future growth.
  • Neutral Sentiment: Reported short interest was zero shares, offering no meaningful indication of short-selling pressure or potential short-covering demand.
  • Negative Sentiment: CEO Sean Duffy disclosed sales of 8,628 shares at an average price of $21.85 and 12,942 shares at $24.81. The transactions reduced his direct ownership by roughly 5% across the reported sales and may weigh on sentiment, although he still owns more than 411,000 shares.
  • Negative Sentiment: At roughly $24 per share, OMDA trades at a very high price-to-earnings ratio near 480, leaving the stock sensitive to disappointment in growth, margins or future earnings. Its recent performance has already placed it well above its 50-day and 200-day moving averages.

Wall Street Analysts Forecast Growth

OMDA has been the subject of several recent analyst reports. Morgan Stanley restated an “overweight” rating and issued a $30.00 price target on shares of Omada Health in a research note on Monday, June 22nd. BMO Capital Markets reiterated an “outperform” rating and set a $24.00 price target on shares of Omada Health in a research report on Friday, August 7th. Wells Fargo & Company raised their price objective on Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of Omada Health in a research note on Friday, May 8th. Finally, Evercore reiterated an “outperform” rating and set a $20.00 target price on shares of Omada Health in a research report on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.75.

View Our Latest Report on Omada Health

About Omada Health

(Get Free Report)

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

Read More

Insider Buying and Selling by Quarter for Omada Health (NASDAQ:OMDA)

Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.